Summary
In the summer of 1990, the Australian Government took a major step by requiring evidence of cost—effectiveness of new medicines prior to reimbursement by the public health care system. This paper assesses whether the methodological principles behind the guidelines are sound and whether they raise important new logistical and policy implications. It is concluded that, while the guidelines may represent the ‘thin end of the wedge’ for the pharmaceutical industry, in that other countries may follow the Australian lead, they also may represent the ‘thin end of the boomerang’ for government. Namely, the development of explicit guidelines for public funding decisions concerning new health technologies places as many demands on funders (the government) as it does on the suppliers (the industry).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bulthuis R. Cimetidine and the cost of peptic ulcer in The Netherlands. Effective Health Care 1 (6): 297–309, 1984
Buxton MJ, Drummond MF. Quality of life measurement in the development of medicines. Pharmaceutical Journal 244 (6574): 260–262, 1989
Chew R, Teeling-Smith G, Wells N. Pharmaceuticals in seven nations, Office of Health Economics, London, 1985
Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis, Department of Health, Housing and Community Services, Canberra, 1990
Department of Health. Improving prescribing. Department of Health, London, 1990
Drummond MF. Studies in economic appraisal in health care, Oxford University Press, Oxford, 1981
Drummond MF. Economic evaluation and the rational diffusion and use of health technology. Health Policy 7: 309–324, 1987
Drummond MF. The role of economic evaluation in the pricing of modem pharmaceutical products. Pharmaceutical Times (December): 32–33, 1989; (January): 10-11; (February): 18-19; (March): 38-42, 1989/90
Drummond MF, Davies LM. Economic analysis alongside clinical trials: revisiting the methodological issues. International Journal of Technology Assessment in Health Care, 1991
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford University Press, Oxford, 1987
Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, et al. Cross—national assessment of health technology. Paper presented at the Health Economists’ Study Group meeting, Oxford, January, 1991
Goldman L, Sia B, Cook F, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long—term beta adrenergic antagonists after acute myocardial infarction. New England Journal of Medicine 319: 152–157, 1988
Jonsson B. A review of the macroeconomic evaluation of cimetidine. In Culyer AJ & Horisberger B (Eds) Economic and medical evaluation of health care technologies, Springer—Verlag, Berlin, 1983
Oster G, Epstein AM. Cost—effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease: the case of cholestyramine. Journal of the American Medical Association 258: 2381–2387, 1987
Schulman KA, Lynn LA, Glick HA, et al. Cost—effectiveness of low dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Annals of Internal Medicine 114 (9): 798–802, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Drummond, M. Australian Guidelines for Cost—Effectiveness Studies of Pharmaceuticals. Pharmacoeconomics 1 (Suppl 1), 61–69 (1992). https://doi.org/10.2165/00019053-199200011-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199200011-00014